Competition Intensifies As Access Increases For US Biosimilars
AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals
• By David Wallace
US biosimilars “will likely go from an average of three competitors to probably upwards of five in every single one of the existing therapeutic markets” • Source: Shutterstock
